Four doses of the Novavax COVID-19 vaccine could give good immunity against new variants

Embargoed until: Publicly released: 2023-01-26 09:00

Australia; International

What does this mean?

Jump to: MultimediaAttachmentsExpert Reaction

Using the Novavax vaccine as a booster could potentially provide a more universal-like response against new SARS-CoV-2 variants, according to researchers at Novavax. The team reported findings from an ongoing phase 2 clinical trial being conducted in Australia and the US, including only participants who received four doses of the Novavax vaccine. They found having 4 doses of Novavax resulted in an immune response to the newer Omicron subvariants (BA.1 and BA.4 or BA.5), and that the responses to the new variants and the original strain were more similar than when only 2 doses were given. They say 4 doses produced a potentially more universal response against the COVID-19 variants. This may be because the parts of the protein provided in the vaccine remain similar across variants, they say.